2026-01-19 – Press Releases – www.prnewswire.com
SHANGHAI, Jan. 19, 2026 /PRNewswire/ — D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: D3S‑003 —…
